MARCO產(chǎn)品信息
別稱:MARCO, SCARA2
物種:Human
屬性:Protein
標(biāo)記:Biotin-labeled/Unconjugated
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>90% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
MARCO分子背景
MARCO也被稱為清道夫受體A類成員2和SCARA2。結(jié)合革蘭氏陽性和革蘭氏陰性細(xì)菌的模式識(shí)別受體(PRR)。也在肺泡巨噬細(xì)胞結(jié)合未經(jīng)聲波處理的顆粒中發(fā)揮作用。與分泌球蛋白SCGB3A2結(jié)合。MARCO連接促進(jìn)巨噬細(xì)胞產(chǎn)生炎癥介質(zhì)。MARCO介導(dǎo)的一些配體的內(nèi)化阻止了它們對(duì)細(xì)胞表面TLR4的激活,但使它們能夠激活細(xì)胞內(nèi)TLR3。MARCO有助于清除凋亡細(xì)胞和吸入細(xì)菌、肥大細(xì)胞介導(dǎo)的矽肺,以及改善過敏原或臭氧誘導(dǎo)的肺部炎癥。它是脾邊緣區(qū)組織和脾巨噬細(xì)胞與B細(xì)胞相互作用所必需的。
關(guān)鍵字: MARCO;MARCO蛋白;SCARA2蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。